Quetiapine XR: Current status for the treatment of major depressive disorder

Chi Un Pae; Manmohandeep Singh Sohi; Ho Jun Seo; Alessandro Serretti; Ashwin A. Patkar; David C. Steffens; Prakash S. Masand

doi:10.1016/j.pnpbp.2010.03.023

Quetiapine XR: Current status for the treatment of major depressive disorder

Chi Un Pae
, Manmohandeep Singh Sohi
, Ho Jun Seo
, Alessandro Serretti
, Ashwin A. Patkar
, David C. Steffens
, Prakash S. Masand

Department of Psychiatry

Duke University
Catholic University of Korea
University of Bologna

Research output: Contribution to journal › Review article › peer-review

45 Scopus citations

Abstract

Quetiapine fumarate extended release (XR) has been approved for treatment of schizophrenia and bipolar disorder. Quetiapine may have antidepressant effects through effects on 5-HT_2A receptor, 5-HT_1A receptor, dopamine receptor, glutamate receptor and norepinephrine transporter. Recently, 7 large-scale randomized, double-blind, placebo (2-studies with active comparator)-controlled clinical trials have demonstrated that quetiapine XR has clinically meaningful efficacy as monotherapy and adjunct therapy to antidepressants for the treatment of adult patients with major depressive disorder (MDD). In such clinical trials, quetiapine XR was generally well tolerated, although weight gain and changes in metabolic parameters, consistent with the known profile of quetiapine, were observed in some patients. As of December 2009, the United States Food and Drug Administration has approved quetiapine XR for the adjunct treatment of MDD. From the data of currently available clinical trials, this review provides an overview of the data and clinical implications for quetiapine XR in the treatment of MDD to enhance clinicians understanding of the use of quetiapine XR in the treatment of MDD.

Original language	English
Pages (from-to)	1165-1173
Number of pages	9
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	34
Issue number	7
DOIs	https://doi.org/10.1016/j.pnpbp.2010.03.023
State	Published - Oct 2010

Bibliographical note

Funding Information:
This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea ( R13-2002-005-04001-0 ).

Funding Information:
The impetus for the preparation of this manuscript originated from the listed authors. AstraZeneca played no role in the conceptualization, design, manuscript preparation or submission of the document. No fees or administrative charges were paid by AstraZeneca for this manuscript. We thank Kate Davenport-Slater PhD of Complete Medical Communications, who provided English editing assistance funded by AstraZeneca.

Keywords

Major depressive disorder
Quetiapine XR

Access to Document

10.1016/j.pnpbp.2010.03.023

Cite this

@article{ddfbc4350f2d4168be1dd7a8606e48a7,

title = "Quetiapine XR: Current status for the treatment of major depressive disorder",

abstract = "Quetiapine fumarate extended release (XR) has been approved for treatment of schizophrenia and bipolar disorder. Quetiapine may have antidepressant effects through effects on 5-HT2A receptor, 5-HT1A receptor, dopamine receptor, glutamate receptor and norepinephrine transporter. Recently, 7 large-scale randomized, double-blind, placebo (2-studies with active comparator)-controlled clinical trials have demonstrated that quetiapine XR has clinically meaningful efficacy as monotherapy and adjunct therapy to antidepressants for the treatment of adult patients with major depressive disorder (MDD). In such clinical trials, quetiapine XR was generally well tolerated, although weight gain and changes in metabolic parameters, consistent with the known profile of quetiapine, were observed in some patients. As of December 2009, the United States Food and Drug Administration has approved quetiapine XR for the adjunct treatment of MDD. From the data of currently available clinical trials, this review provides an overview of the data and clinical implications for quetiapine XR in the treatment of MDD to enhance clinicians understanding of the use of quetiapine XR in the treatment of MDD.",

keywords = "Major depressive disorder, Quetiapine XR",

author = "Pae, \{Chi Un\} and Sohi, \{Manmohandeep Singh\} and Seo, \{Ho Jun\} and Alessandro Serretti and Patkar, \{Ashwin A.\} and Steffens, \{David C.\} and Masand, \{Prakash S.\}",

note = "Funding Information: This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea ( R13-2002-005-04001-0 ). Funding Information: The impetus for the preparation of this manuscript originated from the listed authors. AstraZeneca played no role in the conceptualization, design, manuscript preparation or submission of the document. No fees or administrative charges were paid by AstraZeneca for this manuscript. We thank Kate Davenport-Slater PhD of Complete Medical Communications, who provided English editing assistance funded by AstraZeneca. ",

year = "2010",

month = oct,

doi = "10.1016/j.pnpbp.2010.03.023",

language = "English",

volume = "34",

pages = "1165--1173",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Quetiapine XR

T2 - Current status for the treatment of major depressive disorder

AU - Pae, Chi Un

AU - Sohi, Manmohandeep Singh

AU - Seo, Ho Jun

AU - Serretti, Alessandro

AU - Patkar, Ashwin A.

AU - Steffens, David C.

AU - Masand, Prakash S.

N1 - Funding Information: This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea ( R13-2002-005-04001-0 ). Funding Information: The impetus for the preparation of this manuscript originated from the listed authors. AstraZeneca played no role in the conceptualization, design, manuscript preparation or submission of the document. No fees or administrative charges were paid by AstraZeneca for this manuscript. We thank Kate Davenport-Slater PhD of Complete Medical Communications, who provided English editing assistance funded by AstraZeneca.

PY - 2010/10

Y1 - 2010/10

N2 - Quetiapine fumarate extended release (XR) has been approved for treatment of schizophrenia and bipolar disorder. Quetiapine may have antidepressant effects through effects on 5-HT2A receptor, 5-HT1A receptor, dopamine receptor, glutamate receptor and norepinephrine transporter. Recently, 7 large-scale randomized, double-blind, placebo (2-studies with active comparator)-controlled clinical trials have demonstrated that quetiapine XR has clinically meaningful efficacy as monotherapy and adjunct therapy to antidepressants for the treatment of adult patients with major depressive disorder (MDD). In such clinical trials, quetiapine XR was generally well tolerated, although weight gain and changes in metabolic parameters, consistent with the known profile of quetiapine, were observed in some patients. As of December 2009, the United States Food and Drug Administration has approved quetiapine XR for the adjunct treatment of MDD. From the data of currently available clinical trials, this review provides an overview of the data and clinical implications for quetiapine XR in the treatment of MDD to enhance clinicians understanding of the use of quetiapine XR in the treatment of MDD.

AB - Quetiapine fumarate extended release (XR) has been approved for treatment of schizophrenia and bipolar disorder. Quetiapine may have antidepressant effects through effects on 5-HT2A receptor, 5-HT1A receptor, dopamine receptor, glutamate receptor and norepinephrine transporter. Recently, 7 large-scale randomized, double-blind, placebo (2-studies with active comparator)-controlled clinical trials have demonstrated that quetiapine XR has clinically meaningful efficacy as monotherapy and adjunct therapy to antidepressants for the treatment of adult patients with major depressive disorder (MDD). In such clinical trials, quetiapine XR was generally well tolerated, although weight gain and changes in metabolic parameters, consistent with the known profile of quetiapine, were observed in some patients. As of December 2009, the United States Food and Drug Administration has approved quetiapine XR for the adjunct treatment of MDD. From the data of currently available clinical trials, this review provides an overview of the data and clinical implications for quetiapine XR in the treatment of MDD to enhance clinicians understanding of the use of quetiapine XR in the treatment of MDD.

KW - Major depressive disorder

KW - Quetiapine XR

UR - https://www.scopus.com/pages/publications/77956421518

U2 - 10.1016/j.pnpbp.2010.03.023

DO - 10.1016/j.pnpbp.2010.03.023

M3 - Review article

C2 - 20307622

AN - SCOPUS:77956421518

SN - 0278-5846

VL - 34

SP - 1165

EP - 1173

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

IS - 7

ER -

Quetiapine XR: Current status for the treatment of major depressive disorder

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this